Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
JAMA Pediatr ; 169(1): 48-55, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25383770

ABSTRACT

IMPORTANCE: Most studies examining the association of prenatal antiretroviral (ARV) exposures with congenital anomalies (CAs) in children born to human immunodeficiency virus (HIV)-infected women have been reassuring, but some evidence suggests an increased risk with specific ARV agents. OBJECTIVE: To evaluate the association of in utero ARV exposures with CAs in HIV-exposed uninfected children. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study design. The Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring of ART Toxicities (SMARTT) Study was performed at 22 US medical centers among 2580 HIV-exposed uninfected children enrolled in the SMARTT Study between March 23, 2007, and June 18, 2012. EXPOSURES: First-trimester exposure to any ARV and to specific ARV medications. MAIN OUTCOMES AND MEASURES: The primary end point was a CA based on physician review of infant physical examinations according to the Antiretroviral Pregnancy Registry modification of the Metropolitan Atlanta Congenital Defects Program. Rates of CAs were estimated overall and by birth year. Logistic regression models were used to evaluate the association of CAs with first-trimester ARV exposures, adjusting for demographic and maternal characteristics. RESULTS: Congenital anomalies occurred in 175 of 2580 children, yielding a prevalence of 6.78% (95% CI, 5.85%-7.82%); 242 major CAs were confirmed, including 72 musculoskeletal and 55 cardiovascular CAs. The prevalence of CAs increased significantly among successive birth cohorts (3.8% for children born before 2002 and up to 8.3% for those born 2008-2010). In adjusted models, no association of first-trimester exposures with CAs was found for any ARV, for combination ARV regimens, or for any drug class. No individual ARV in the reverse transcriptase inhibitor drug classes was associated with an increased risk of CAs. Among protease inhibitors, higher odds of CAs were observed for atazanavir sulfate (adjusted odds ratio [aOR], 1.95; 95% CI, 1.24-3.05) and for ritonavir used as a booster (aOR, 1.56; 95% CI, 1.11-2.20). With first-trimester atazanavir exposure, risks were highest for skin (aOR, 5.23) and musculoskeletal (aOR, 2.55) CAs. CONCLUSIONS AND RELEVANCE: Few individual ARVs and no drug classes were associated with an increased risk of CAs in HIV-exposed infants after adjustment for calendar year and maternal characteristics. While the overall risk remained low, a relative increase was observed in successive years and with atazanavir exposure. Given the low absolute CA risk, the benefits of recommended ARV therapy use during pregnancy still outweigh such risks, although further studies are warranted.


Subject(s)
Abnormalities, Drug-Induced/etiology , Anti-Retroviral Agents/adverse effects , HIV Infections/drug therapy , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious/drug therapy , Prenatal Exposure Delayed Effects/chemically induced , Abnormalities, Drug-Induced/epidemiology , Female , Georgia/epidemiology , HIV Infections/transmission , Humans , Infant, Newborn , Pregnancy , Pregnancy Trimester, First , Prenatal Exposure Delayed Effects/epidemiology , Prevalence , Prospective Studies , Risk Factors , Treatment Outcome
2.
J Infect Dis ; 207(4): 612-21, 2013 Feb 15.
Article in English | MEDLINE | ID: mdl-23204173

ABSTRACT

BACKGROUND: Use of antiretroviral drugs (ARVs) during pregnancy has been associated with higher risk of preterm birth. METHODS: The Pediatric HIV/AIDS Cohort Study network's Surveillance Monitoring for ART Toxicities study is a US-based cohort of human immunodeficiency virus (HIV)-exposed uninfected children. We evaluated maternal ARV use during pregnancy and the risk of any type of preterm birth (ie, birth before 37 completed weeks of gestation), the risk of spontaneous preterm birth (ie, preterm birth that occurred after preterm labor or membrane rupture, without other complications), and the risk of small for gestational age (SGA; ie, a birth weight of <10th percentile for gestational age). Multivariable logistic regression models were used to evaluate the association of ARVs and timing of exposure, while adjusting for maternal characteristics. RESULTS: Among 1869 singleton births, 18.6% were preterm, 10.2% were spontaneous preterm, and 7.3% were SGA. A total of 89% used 3-drug combination ARV regimens during pregnancy. In adjusted models, the odds of preterm birth and spontaneous preterm birth were significantly greater among mothers who used protease inhibitors during the first trimester (adjusted odds ratios, 1.55 and 1.59, respectively) but not among mothers who used nonnucleoside reverse-transcriptase inhibitor or triple-nucleoside regimens during the first trimester. Combination ARV exposure starting later in pregnancy was not associated with increased risk. No associations were observed between SGA and exposure to combination ARV regimens. CONCLUSIONS: Protease inhibitor use early in pregnancy may be associated with increased risk for prematurity.


Subject(s)
Anti-HIV Agents/adverse effects , HIV Infections/drug therapy , HIV Protease Inhibitors/adverse effects , Pregnancy Complications, Infectious/drug therapy , Premature Birth/epidemiology , Reverse Transcriptase Inhibitors/adverse effects , Adult , Anti-HIV Agents/therapeutic use , Cohort Studies , Drug Therapy, Combination , Female , Gestational Age , HIV Protease Inhibitors/therapeutic use , Humans , Infant, Low Birth Weight , Infant, Newborn , Infant, Premature , Pregnancy , Reverse Transcriptase Inhibitors/therapeutic use , Risk Factors , Young Adult
3.
AIDS ; 26(9): 1151-9, 2012 Jun 01.
Article in English | MEDLINE | ID: mdl-22382151

ABSTRACT

OBJECTIVE: To evaluate the association of tenofovir disoproxil fumarate (TDF) use during pregnancy with early growth parameters in HIV-exposed, uninfected (HEU) infants. DESIGN: US-based prospective cohort study of HEU children to examine potential adverse effects of prenatal TDF exposure. METHODS: We evaluated the association of maternal TDF use during pregnancy with small for gestational age (SGA); low birth weight (LBW, <2.5 kg); weight-for-age z-scores (WAZ), length-for-age z-scores (LAZ), and head circumference-for-age (HCAZ) z-scores at newborn visit; and LAZ, HCAZ, and WAZ at age 1 year. Logistic regression models for LBW and SGA were fit, adjusting for maternal and sociodemographic factors. Adjusted linear regression models were used to evaluate LAZ, WAZ, and HCAZ by TDF exposure. RESULTS: Of 2029 enrolled children with maternal antiretroviral information, TDF was used by 449 (21%) HIV-infected mothers, increasing from 14% in 2003 to 43% in 2010. There was no difference between those exposed to combination regimens with vs. without TDF for SGA, LBW, and newborn LAZ and HCAZ. However, at age 1 year, infants exposed to combination regimens with TDF had significantly lower adjusted mean LAZ and HCAZ than those without TDF (LAZ: -0.17 vs. -0.03, P=0.04; HCAZ: 0.17 vs. 0.42, P=0.02). CONCLUSION: TDF use during pregnancy was not associated with increased risk for LBW or SGA. The slightly lower mean LAZ and HCAZ observed at age 1 year in TDF-exposed infants are of uncertain significance but underscore the need for additional studies of growth outcomes after TDF use during pregnancy.


Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/adverse effects , Body Size/drug effects , HIV Infections/drug therapy , Infant, Newborn/growth & development , Organophosphonates/adverse effects , Pregnancy Complications, Infectious/drug therapy , Adenine/adverse effects , Child Development , Drug Therapy, Combination/adverse effects , Female , Humans , Infant , Infant, Low Birth Weight , Infant, Small for Gestational Age , Male , Pregnancy , Prospective Studies , Risk Factors , Tenofovir
4.
Pediatr Infect Dis J ; 30(2): 175-6, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20885334

ABSTRACT

In this study, we report 4 infants who developed severe ocular reactions after neonatal ocular prophylaxis with gentamicin ophthalmic ointment during a period of erythromycin ophthalmic ointment shortage. In light of this experience, gentamicin ophthalmic ointment should not be used as an alternative for neonatal ocular prophylaxis.


Subject(s)
Anti-Bacterial Agents/adverse effects , Antibiotic Prophylaxis/adverse effects , Gentamicins/adverse effects , Ointments/adverse effects , Ophthalmia Neonatorum/prevention & control , Anti-Bacterial Agents/administration & dosage , Antibiotic Prophylaxis/methods , Gentamicins/administration & dosage , Humans , Infant, Newborn , Ointments/administration & dosage
5.
Pharmacotherapy ; 29(12): 1491, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19947808

ABSTRACT

Mitochondrial toxicity is a well-recognized adverse effect of nucleoside reverse transcriptase inhibitor therapy for human immunodeficiency virus (HIV) infection. Transient lactic acidosis is often observed in children born after in utero antiretroviral prophylaxis against mother-to-child transmission of HIV. However, the extent and the mechanism of in utero adverse effects are largely unknown. We describe a 4-year-old girl who presented with manifestations of severe mitochondrial disease, specifically, developmental and growth delay, hypotonia, lactic acidosis, congenital cataracts, and pancreatitis. Her HIV-positive mother was receiving lamivudine, zidovudine, and nelfinavir mesylate during her pregnancy. The child tested HIV negative after birth. She was found to have a homoplastic T9098C sequence change in the mitochondrial gene coding for adenosine 5'-triphosphate synthase 6 (MTATP6) that was previously reported as a mitochondrial polymorphism. This polymorphism is in the MTATP6 gene-coding sequence and leads to the replacement of a nonpolar amino acid with a polar amino acid. Because of the typical clinical manifestations of mitochondrial disorder and because of the nature of the mitochondrial sequence change, the observed polymorphism likely predisposed this patient to develop severe antiretroviral-associated mitochondrial disease. Mitochondrial sequence alterations may be important factors in mitochondrial toxicity associated with antiretroviral treatment. Mitochondrial sequencing may be warranted in cases of persistent lactic acidosis after antiretroviral prophylaxis to further study this association.


Subject(s)
Anti-HIV Agents/adverse effects , Infectious Disease Transmission, Vertical/prevention & control , Mitochondrial Diseases/chemically induced , Mitochondrial Proton-Translocating ATPases/drug effects , Anti-HIV Agents/therapeutic use , Base Sequence , Child, Preschool , DNA, Mitochondrial/drug effects , DNA, Mitochondrial/genetics , Female , HIV Infections/drug therapy , HIV Infections/prevention & control , HIV Infections/transmission , Humans , Mitochondrial Diseases/genetics , Mitochondrial Diseases/physiopathology , Mitochondrial Proton-Translocating ATPases/genetics , Pregnancy , Severity of Illness Index
6.
Clin Infect Dis ; 48(3): 338-46, 2009 Feb 01.
Article in English | MEDLINE | ID: mdl-19115969

ABSTRACT

BACKGROUND: A previous analysis of children infected with human immunodeficiency virus (HIV) in the Women and Infants Transmission Study showed a strong correlation between low activated CD8(+) T lymphocytes in the first 2 months of life and good immunological prognosis. We sought to extend these observations to neurodevelopmental prognosis. METHODS: Ninety-eight HIV-infected children born before 1994 with flow cytometric data from the first 2 months of life and adequate neurodevelopmental testing through age 30 months were studied. Children were divided into those with low (5% CD8(+)HLA-DR(+) cells or >25% CD8(+)CD38(+) cells) immune activation at 1 and/or 2 months of age. Analysis was performed using survival analysis, Cox's proportional hazard regression, and longitudinal regression models. RESULTS: Absence of immune activation, measured as

Subject(s)
CD8-Positive T-Lymphocytes/immunology , Central Nervous System Diseases/immunology , Central Nervous System Diseases/virology , Central Nervous System/growth & development , HIV Infections/complications , HIV Infections/immunology , Adolescent , Adult , Cohort Studies , Female , HIV Infections/diagnosis , Humans , Infant , Infant, Newborn , Mental Processes , Prospective Studies , Psychomotor Performance
7.
Pediatrics ; 122(2): 331-9, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18676551

ABSTRACT

OBJECTIVE: In this study, we tested the hypothesis that the CD4(+)/CD8(+) T cell ratio could predict HIV infection status in HIV-exposed infants. METHODS: CD4(+)/CD8(+) T cell ratios were determined from data for live-born singleton infants who had been prospectively enrolled in the Women and Infants Transmission Study. Data for 2208 infants with known HIV infection status (179 HIV-infected and 2029 uninfected infants) were analyzed. RESULTS: Receiver operating characteristic curves indicated that the CD4(+)/CD8(+) T cell ratio performed better than the proportion of CD4(+) T cells for diagnosis of HIV infection as early as 2 months of age, and this relationship was unaffected by adjustment for maternal race/ethnicity, infant birth weight, gestational age, and gender. At 4 months of age, 90% specificity for HIV diagnosis was associated with 60% sensitivity. For ease of use, graphical estimates based on cubic splines for the time-dependent parameters in a Box-Cox transformation (L), the median (M), and the coefficient of variation (S) were used to create LMS centile curves to show the sensitivity and specificity of CD4(+)/CD8(+) T cell ratios in HIV-infected and uninfected infants until 12 months of age. At 6 months of age, a simplified equation that incorporated sequential CD4(+)/CD8(+) T cell ratios and hematocrit values resulted in improved receiver operating characteristic curves, with 94% positive predictive value and 98% negative predictive value. The positive and negative predictive values remained above 90% in simulated infant populations over a wide range of HIV infection prevalence values. CONCLUSIONS: In the absence of virological diagnosis, a presumptive diagnosis of HIV infection status can be made on the basis of CD4(+)/CD8(+) T cell ratios in HIV-1-exposed infants after 2 months of age; sensitivity and specificity can be improved at 6 months by using a discriminant analysis equation.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , HIV Infections/transmission , Infectious Disease Transmission, Vertical/statistics & numerical data , Pregnancy Complications, Infectious/diagnosis , Analysis of Variance , Biomarkers/blood , Case-Control Studies , Cohort Studies , Female , Follow-Up Studies , HIV Infections/diagnosis , HIV Infections/epidemiology , HIV Seropositivity , Humans , Incidence , Infant, Newborn , Male , Multivariate Analysis , Predictive Value of Tests , Pregnancy , Pregnancy Complications, Infectious/epidemiology , Probability , Prospective Studies , ROC Curve , Sensitivity and Specificity , Severity of Illness Index , Sex Distribution
8.
J Allergy Clin Immunol ; 122(1): 159-65, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18547627

ABSTRACT

BACKGROUND: Immunoreconstitution of HIV(+) patients after treatment with highly active antiretroviral therapy (HAART) appears to provoke inflammatory diseases. OBJECTIVE: We sought to determine whether HIV(+) children receiving HAART (HIV(+) HAART(+)) have a higher incidence of asthma than HIV(+) children not receiving HAART (HIV(+) HAART(-)). METHODS: Two thousand six hundred sixty-four children (193 HIV(+) and 2471 HIV(-) children) born to HIV(+) women were evaluated for the incidence and prevalence of asthma (ie, asthma medication use) and change of CD4(+) T-cell percentage with time. RESULTS: The HIV(+) HAART(+) children had higher CD4(+) T-cell percentages, lower CD8(+) T-cell percentages, and lower viral burdens than the HIV(+) HAART(-) children (P < or = .05 to P < or = .01). The cumulative incidence of asthma medication use in HIV(+) HAART(+) children at 13.5 years increased to 33.5% versus 11.5% in HIV(+) HAART(-) children (hazard ratio, 3.34; P = .01) and was equal to that in the HIV(-) children. In children born before the HAART era, the prevalence of asthma medication use for HIV(+) HAART(+) children at 11 years of age was 10.4% versus 3.8% for HIV(+) HAART(-) children (odds ratio, 3.38; P = .02) and was equal to that of the HIV(-) children. The rate of change of CD4(+) T cells around the time of first asthma medication for HIV(+) HAART(+) versus HIV(+) HAART(-) children was 0.81%/y versus -1.43%/y (P = .01). CONCLUSION: The increased incidence of asthma in HIV(+) HAART(+) children might be driven by immunoreconstitution of CD4(+) T cells.


Subject(s)
Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Asthma/epidemiology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , HIV Infections/drug therapy , Asthma/etiology , Asthma/immunology , CD4 Lymphocyte Count , Cohort Studies , Female , HIV Infections/immunology , HIV Infections/virology , Humans , Incidence , Infant , Male
9.
J Asthma ; 44(10): 855-9, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18097863

ABSTRACT

We identified main asthma risk factors for children living in the South Bronx, where asthma rates are eight times higher than the national average. This case-control study enrolled 261 children at Lincoln Medical and Mental Health Center from 2002 to 2003. We questioned the mothers on medical history and home environment. The most important risk factors for asthma in the South Bronx pediatric population are Hispanic ethnicity, family history of asthma, and exposure to tobacco smoke. South Bronx children limited to breast-feeding during the first 3 months of age are less likely to develop asthma.


Subject(s)
Asthma/epidemiology , Case-Control Studies , Child, Preschool , Humans , New York City/epidemiology , Risk Factors
10.
Clin Infect Dis ; 34(7): 991-1001, 2002 Apr 01.
Article in English | MEDLINE | ID: mdl-11880966

ABSTRACT

The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to

Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV-1 , Reverse Transcriptase Inhibitors/therapeutic use , Anti-HIV Agents/adverse effects , CD4-Positive T-Lymphocytes/drug effects , Child , Child, Preschool , Drug Therapy, Combination , Female , Humans , Lamivudine/therapeutic use , Male , Nelfinavir/adverse effects , Nelfinavir/therapeutic use , Nevirapine/adverse effects , Nevirapine/therapeutic use , RNA, Viral/drug effects , RNA, Viral/metabolism , Reverse Transcriptase Inhibitors/adverse effects , Ritonavir/adverse effects , Ritonavir/therapeutic use , Stavudine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...